Abstract
Serum dopamine-beta-hydroxylase (DBH) activity has been reported to be raised in some patients with neuoblastoma but this has been challenged. We have studied serum DBH levels on 26 children with neuroblastoma and 58 age-matched controls. Only in 2 patients were the levels higher than in the controls, and then only transiently. In both, the rise in DBH levels could be accounted for by the transfusion of adult blood. Serum DBH levels in children with neuroblastoma were unrelated to the response of this neoplasm to treatment or to urinary catecholamine output and thus are unlikely to have any value in diagnosis or as a marker of tumour activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Eldeeb, B., Burns, S., Robinson, R. et al. Serum dopamine β hydroxylase in children with neuroblastoma. Br J Cancer 47, 115–121 (1983). https://doi.org/10.1038/bjc.1983.14
Issue Date:
DOI: https://doi.org/10.1038/bjc.1983.14
This article is cited by
-
Dopamine-beta-hydroxylase in patients with cystic fibrosis
European Journal of Pediatrics (1986)
